On February 26, 2016, CBS New York spotlighted the Taming Aging with Metformin (TAME) Trial led by two-time grantee and Deputy Scientific Director, Nir Barzilai, MD.
In the segment, Dr. Barzilai notes that in combination with diet and exercise, pharmacological interventions, such as Metformin, show promise for extending healthspan. “What we’re trying to do is change it so that as they age, they’re healthy,” he explained.
Spearheaded by Barzilai and AFAR Scientific Director Steven Austand, PhD, with board members board members S. Jay Olshansky, Phd, and James Kirkland, MD, Phd, TAME is a novel study that will test whether Metformin can delay the onset of age-related diseases and conditions including cancer, cardio vascular disease, type 2 diabetes, and cognitive decline. If this study succeeds, it will pave the way for the Food and Drug Administration (FDA) to consider aging as a treatable condition. Learn more here.
